There are a number of potentially druggable stress pathways [107] and genetic manipulation or pharmacological inhibition of the ATF4–CHOP–GADD34 pathway has shown therapeutic benefit in the trabecular meshwork in murine and human glaucoma [108,109].This cellular model of pseudoexfoliation glaucoma cannot capture all features of this complex disease, but can provide some insight into disease pathogenesis and support the development of novel therapeutic interventions. The gene discussed is ATF4; the disease is glaucoma.